Form 4: Ikena Oncology Director Acquires Stock Options
SEC Form 4 Filing
Richard Wooster, a director of Ikena Oncology, acquired 17,520 stock options on June 7, 2024, at an exercise price of $1.75.
Summary
- Richard Wooster, a director at Ikena Oncology, acquired 17,520 stock options on June 7, 2024.
- The exercise price for these options is $1.75.
- The options vest fully on the earlier of June 7, 2025, or the date of the next annual meeting, contingent upon continued service as a director.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, as it simply reports a transaction.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical and biotechnology industries. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of transaction: Richard Wooster acquired stock options. |
| 06/07/2025 | Earliest vesting date for the stock options. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.